Research Study

Functional Brain Networks Underlying Non-pharmaceutical Interventions for Psychosis
Principal Investigator 
Todd Woodward

Overview

Body Locations and Systems 
Brain
Disorders and Conditions 
Schizophrenia
ClinicalTrials.gov# 
NCT01764568
Status 
Recruiting
Study Start/End 
Oct 15, 2012 to Sep 15, 2018
Locations 
UBC Hospital
Name/Title 
Sarah Flann, Research Coordinator
Phone 
604-347-6467
Purpose of Study 

Current Canadian Clinical Practice guidelines emphasize the need for effective psychosocial adjuncts to pharmacotherapy for schizophrenia (Canadian Psychiatric Association 2005). This randomized control trial seeks to contribute to the body of evidence supporting psychosocial treatments by assessing the effectiveness of metacognitive training (MCT) and cognitive remediation (CR) at treating the persistent positive and cognitive symptoms of schizophrenia. MCT is a therapy designed to improve patient awareness and insight into the cognitive biases that are frequently seen in schizophrenia; it has been associated with decreased psychopathology (specifically decreased positive symptoms) and improved psychosocial function. CR is a therapy designed to improve performance in a variety of neurocognitive functions such as attention, memory, and executive functioning; it has been associated with improved cognitive and psychosocial functioning. Both MCT and CR will be compared to treatment as usual (TAU) as done previously (Kumar er al., 2010; Moritz et al., 2011).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.